Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose psilocybin and ketamine for emotional and cognitive symptoms in Parkinson's disease
NL-OMON52045Phase 2Withdrawn
- Sponsor
- Maastricht University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin and ketamine, sponsored by Maastricht University. Planned start Nov 2021; status: withdrawn.
02
Drugs
psilocybinketamine
Beyond the preview
Go deeper on NL-OMON52045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52045.